Company · founded 2005
Integrated BioTherapeutics (United States)
Gaithersburg, United States · integratedbiotherapeutics.com
- Citations, last 5 years
- 177
- Works, last 5 years
- 31
- h-index
- 76
- Scientists listed
- 2
- Grants since 2016
- 78
Grants received
2025–2027 · research · R44
Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Sunil Gandhi · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2025–2026 · research · R43
The Next Wave of Asthma Therapeutics
Josep Bassaganya-Riera · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2025 · research · R43
Next-Gen Oral Therapeutics for Type 2 Diabetes
Josep Bassaganya-Riera · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2024–2026 · grant · Standard Grant
STTR Phase I: Novel Bio-Intervention to Attenuate Neurological Damage Following Traumatic Brain Injury
William Ferguson · Integrated BioTherapeutics (United States) · funded by National Science Foundation
2024–2025 · research · R43
Developing a Novel Biologic Therapy to Eradicate Brain Cancer and Brain Metastasis
Donald Davidson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2024–2025 · research · R43
Development of Novel Therapeutics for Asthma
Josep Bassaganya-Riera · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Immunoregulatory Therapeutics for Ulcerative Colitis
Andrew Leber · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2023–2024 · research · R43
Development of a novel depot delivery system for a glaucoma therapeutic
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2023–2026 · grant · OCRP
Unleashing the Full Potential of Checkpoint Inhibitor Antibodies with T-Cell-Stimulating Oncolytic Adenoviruses for Treatment of Ovarian Cancer
Akseli Hemminki · Integrated BioTherapeutics (United States) · funded by Congressionally Directed Medical Research Programs
2023–2024 · research · R43
Development of a novel depot delivery system for a glaucoma therapeutic
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Development of Novel Topical Therapeutics for Psoriasis
Nuria Tubau Juni · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2023–2024 · research · R43
Development of a novel depot delivery system for a glaucoma therapeutic
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R43
An oral TNFα inhibitor for inflammatory bowel disease
Grant H Risdon · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease
Sunil Gandhi · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Development of Therapeutic Products for Marburg Virus
M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Neuroprotective Properties of a Novel Glaucoma Drug and Formulation
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathies
Sunil Gandhi · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Immunotherapy of MRSA Osteomyelitis
M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Targeting the Immunometabolic Hub Nlrx1 as a Novel Therapeutic for Asthma
Josep Bassaganya-Riera · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Immunotherapy of MRSA Osteomyelitis
M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
Gaya K. Amarasinghe · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2025 · research · R01
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2025 · research · R01
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
Nathan K. Archer · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Development of a non-opioid chemogenetic therapy for chronic neuropathic pain
Annahita Keravala · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R43
VIRAL DELIVERED CARDIAC REGENERATION
Bhawanjit K Brar · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2023 · research · R01
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2023 · research · R41
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
Gaya K. Amarasinghe · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)
Gary Jay Brenner · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Development of a non-opioid chemogenetic therapy for chronic neuropathic pain
Annahita Keravala · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Validation of Immunometabolic NLRX1 Therapeutics for IBD
Andrew Leber · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R43
ISTAb- A novel therapy to target staphylococcal toxins at the site of infections
Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Mining natively paired macque antibodies for Marburg virus protective antibodies
Shweta Kailasan · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma
Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R44
Development of a Universal Immunotherapeutic for Influenza Viruses
Frederick Wayne Holtsberg · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R41
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2022 · research · R43
ISTAb- A novel therapy to target staphylococcal toxins at the site of infections
Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019–2023 · research · R44
Development of a Universal Immunotherapeutic for Influenza Viruses
Frederick Wayne Holtsberg · Integrated BioTherapeutics (United States) · funded by National Institutes of Health
2019 · research · R43
Development of Antibiotic-Free Clostridium difficile Therapeutics
Raquel Hontecillas · Integrated BioTherapeutics (United States) · funded by National Institutes of Health